Skip to main content
SpringerLink
Log in

Molecular-Targeted Therapies in Hepatocellular Carcinoma

  • Chapter
  • First Online:
Hepatocellular Carcinoma

Part of the book series: Molecular and Translational Medicine ((MOLEMED))

Abstract

The management of patients with advanced-stage hepatocellular carcinoma (HCC) has changed dramatically over the past year. Partial hepatectomy, liver transplantation, ablation, radiation therapy, and embolization procedures remain important interventions for localized HCC, whereas systemic therapy is the cornerstone of therapy for patients with extrahepatic disease. Since 2017, several agents, including regorafenib, lenvatinib, cabozantinib, ramucirumab, nivolumab, and pembrolizumab, have been approved or are likely approved as first- and second-line therapies by Food and Drug Administration (FDA) for systemic treatment of advanced-stage HCC. In this chapter, we overview the molecular mechanisms underlying HCC and how improved understanding of these pathways has helped the development of targeted therapies. We also discuss the value of these molecular-targeted therapeutic agents, safety profile, and their impact on personalization of HCC therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. https://doi.org/10.3322/caac.21387.

    Article  PubMed  Google Scholar 

  2. (NCCN) NCCN. NNCN Guidelines version 1.2018 Hepatocellular carcinoma. 2017. https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Accessed 24 Feb 2018.

  3. Cheng A-L, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, et al. Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC). J Clin Oncol. 2017;35(15_suppl):4001. https://doi.org/10.1200/JCO.2017.35.15_suppl.4001.

    Article  Google Scholar 

  4. Kelley RK, Verslype C, Cohn AL, Yang TS, Su WC, Burris H, et al. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study. Ann Oncol. 2017;28(3):528–34. https://doi.org/10.1093/annonc/mdw651.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Finn RS, Chan SL, Zhu AX, Knox JJ, Cheng A-L, Siegel AB, et al. KEYNOTE-240: randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma. J Clin Oncol. 2017;35(4_suppl):TPS503-TPS. https://doi.org/10.1200/JCO.2017.35.4_suppl.TPS503.

    Article  Google Scholar 

  6. Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54–63. https://doi.org/10.1056/NEJMoa1717002.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Shibata T, Arai Y, Totoki Y. Molecular genomic landscapes of hepatobiliary cancer. Cancer Sci. 2018;109(5):1282–91. https://doi.org/10.1111/cas.13582.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Dhanasekaran R, Bandoh S, Roberts LR. Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances. F1000Res. 2016;5:F1000 Faculty Rev-879. https://doi.org/10.12688/f1000research.6946.1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Tanabe KK, Lemoine A, Finkelstein DM, Kawasaki H, Fujii T, Chung RT, et al. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA. 2008;299(1):53–60. https://doi.org/10.1001/jama.2007.65.

    Article  CAS  PubMed  Google Scholar 

  10. Goyal L, Muzumdar MD, Zhu AX. Targeting the HGF/c-MET pathway in hepatocellular carcinoma. Clin Cancer Res. 2013;19(9):2310–8. https://doi.org/10.1158/1078-0432.CCR-12-2791.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Bocca C, Novo E, Miglietta A, Parola M. Angiogenesis and fibrogenesis in chronic liver diseases. Cell Mol Gastroenterol Hepatol. 2015;1(5):477–88. https://doi.org/10.1016/j.jcmgh.2015.06.011.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Dai L, Peng XX, Tan EM, Zhang JY. Tumor-associated antigen CAPERalpha and microvessel density in hepatocellular carcinoma. Oncotarget. 2016;7(13):16985–95. https://doi.org/10.18632/oncotarget.7707.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Cannito S, Turato C, Paternostro C, Biasiolo A, Colombatto S, Cambieri I, et al. Hypoxia up-regulates SERPINB3 through HIF-2alpha in human liver cancer cells. Oncotarget. 2015;6(4):2206–21. https://doi.org/10.18632/oncotarget.2943.

    Article  PubMed  Google Scholar 

  14. Tella SH, Taieb D, Pacak K. HIF-2alpha: Achilles’ heel of pseudohypoxic subtype paraganglioma and other related conditions. Eur J Cancer. 2017;86:1–4. https://doi.org/10.1016/j.ejca.2017.08.023.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Lai JP, Thompson JR, Sandhu DS, Roberts LR. Heparin-degrading sulfatases in hepatocellular carcinoma: roles in pathogenesis and therapy targets. Future Oncol. 2008;4(6):803–14. https://doi.org/10.2217/14796694.4.6.803.

    Article  CAS  PubMed  Google Scholar 

  16. Aaronson DS, Horvath CM. A road map for those who don’t know JAK-STAT. Science. 2002;296(5573):1653–5. https://doi.org/10.1126/science.1071545.

    Article  CAS  PubMed  Google Scholar 

  17. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology. 2006;130(4):1117–28. https://doi.org/10.1053/j.gastro.2006.01.006.

    Article  CAS  PubMed  Google Scholar 

  18. Pez F, Lopez A, Kim M, Wands JR, Caron de Fromentel C, Merle P. Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. J Hepatol. 2013;59(5):1107–17. https://doi.org/10.1016/j.jhep.2013.07.001.

    Article  CAS  PubMed  Google Scholar 

  19. Goossens N, Sun X, Hoshida Y. Molecular classification of hepatocellular carcinoma: potential therapeutic implications. Hepat Oncol. 2015;2(4):371–9. https://doi.org/10.2217/hep.15.26.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Rao S, Mishra L. Targeting TGF-beta signaling in liver cancer. Hepatology. 2018; https://doi.org/10.1002/hep.30426.

  21. Fabregat I, Caballero-Diaz D. Transforming growth factor-beta-induced cell plasticity in liver fibrosis and hepatocarcinogenesis. Front Oncol. 2018;8:357. https://doi.org/10.3389/fonc.2018.00357.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Tai WT, Cheng AL, Shiau CW, Huang HP, Huang JW, Chen PJ, et al. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J Hepatol. 2011;55(5):1041–8. https://doi.org/10.1016/j.jhep.2011.01.047.

    Article  CAS  PubMed  Google Scholar 

  23. Wei JC, Meng FD, Qu K, Wang ZX, Wu QF, Zhang LQ, et al. Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1. Acta Pharmacol Sin. 2015;36(2):241–51. https://doi.org/10.1038/aps.2014.122.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Sprinzl MF, Puschnik A, Schlitter AM, Schad A, Ackermann K, Esposito I, et al. Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion. J Hepatol. 2015;62(4):863–70. https://doi.org/10.1016/j.jhep.2014.11.011.

    Article  CAS  PubMed  Google Scholar 

  25. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. https://doi.org/10.1016/S1470-2045(08)70285-7.

    Article  CAS  PubMed  Google Scholar 

  26. Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, et al. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and of its treatment with sorafeNib): second interim analysis. Int J Clin Pract. 2014;68(5):609–17. https://doi.org/10.1111/ijcp.12352.

    Article  CAS  PubMed  Google Scholar 

  27. Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA. 2010;304(19):2154–60. https://doi.org/10.1001/jama.2010.1672.

    Article  CAS  PubMed  Google Scholar 

  28. Abou-Alfa GK, Niedzwieski D, Knox JJ, Kaubisch A, Posey J, Tan BR, et al. Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance). J Clin Oncol. 2016;34(4_suppl):192. https://doi.org/10.1200/jco.2016.34.4_suppl.192.

    Article  Google Scholar 

  29. Wang B, Xu H, Gao ZQ, Ning HF, Sun YQ, Cao GW. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol. 2008;49(5):523–9. https://doi.org/10.1080/02841850801958890.

    Article  CAS  PubMed  Google Scholar 

  30. Chao Y, Chung YH, Han G, Yoon JH, Yang J, Wang J, et al. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial. Int J Cancer. 2015;136(6):1458–67. https://doi.org/10.1002/ijc.29126.

    Article  CAS  PubMed  Google Scholar 

  31. Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, TACTICS trial group. Randomized, open label, multicenter, phase II trial comparing transarterial chemoembolization (TACE) plus sorafenib with TACE alone in patients with hepatocellular carcinoma (HCC): TACTICS trial. ASCO, ASCO Gastrointestinal symposium. J Clin Oncol. 2018;36(suppl 4S; abstr 206):2018. Accessed 25 Feb 2018.

    Google Scholar 

  32. Meyer T, Fox R, Ma YT, Ross PJ, James MW, Sturgess R, et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2017;2(8):565–75. https://doi.org/10.1016/S2468-1253(17)30156-5.

    Article  PubMed  Google Scholar 

  33. de Jesus VHF, Dettino ALA. Update on hepatocellular carcinoma from the 2018 Gastrointestinal Cancer Symposium (ASCO GI). J Hepatocell Carcinoma. 2018;5:87–90. https://doi.org/10.2147/JHC.S171396.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Shang J, Xu S, Zhang J, Ran X, Bai L, Tang H. Efficacy of sorafenib in patients with hepatocellular carcinoma after resection: a meta-analysis. Oncotarget. 2017;8(65):109723–31. https://doi.org/10.18632/oncotarget.21299.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Bruix J, Qin S, Merle P, Granito A, Huang Y-H, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 389(10064):56–66. https://doi.org/10.1016/S0140-6736(16)32453-9.

  36. Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. https://doi.org/10.1016/S0140-6736(18)30207-1.

  37. Zhu AX, Baron AD, Malfertheiner P, Kudo M, Kawazoe S, Pezet D, et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: analysis of REACH trial results by Child-Pugh score. JAMA Oncol. 2016; https://doi.org/10.1001/jamaoncol.2016.4115.

  38. Zhu AX, Kang Y, Yen C, Finn RS, Galle PR, Llovet JM, et al. REACH-2: a randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib. J Clin Oncol. 2018;36((15) supp)

    Google Scholar 

  39. Barone C, Basso M, Biolato M, Pompili M, Rufini V, Miele L, et al. A phase II study of sunitinib in advanced hepatocellular carcinoma. Dig Liver Dis. 2013;45(8):692–8. https://doi.org/10.1016/j.dld.2013.01.002.

    Article  CAS  PubMed  Google Scholar 

  40. Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013;31(32):4067–75. https://doi.org/10.1200/JCO.2012.45.8372.

    Article  CAS  PubMed  Google Scholar 

  41. Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol. 2013;14(1):55–63. https://doi.org/10.1016/S1470-2045(12)70490-4.

    Article  CAS  PubMed  Google Scholar 

  42. Rimassa L, Assenat E, Peck-Radosavljevic M, Pracht M, Zagonel V, Mathurin P, et al. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol. 2018;19(5):682–93. https://doi.org/10.1016/S1470-2045(18)30146-3.

    Article  CAS  PubMed  Google Scholar 

  43. Rebouissou S, La Bella T, Rekik S, Imbeaud S, Calatayud AL, Rohr-Udilova N, et al. Proliferation markers are associated with MET expression in hepatocellular carcinoma and predict tivantinib sensitivity in vitro. Clin Cancer Res. 2017;23(15):4364–75. https://doi.org/10.1158/1078-0432.CCR-16-3118.

    Article  CAS  PubMed  Google Scholar 

  44. Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24(12):1898–903. https://doi.org/10.1200/jco.2005.04.9130.

    Article  CAS  PubMed  Google Scholar 

  45. Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008;26(18):2992–8. https://doi.org/10.1200/jco.2007.15.9947.

    Article  CAS  PubMed  Google Scholar 

  46. Zhu AX, Ancukiewicz M, Supko JG, Sahani DV, Blaszkowsky LS, Meyerhardt JA, et al. Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study. Clin Cancer Res. 2013;19(6):1557–66. https://doi.org/10.1158/1078-0432.ccr-12-3041.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol. 2015;33(2):172–9. https://doi.org/10.1200/JCO.2013.54.3298.

    Article  CAS  PubMed  Google Scholar 

  48. Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol. 2013;31(28):3517–24. https://doi.org/10.1200/jco.2012.48.4410.

    Article  CAS  PubMed  Google Scholar 

  49. Kanai F, Yoshida H, Tateishi R, Sato S, Kawabe T, Obi S, et al. A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2011;67(2):315–24. https://doi.org/10.1007/s00280-010-1320-2.

    Article  CAS  PubMed  Google Scholar 

  50. Kudo M, Cheng A-L, Park J-W, Park JH, Liang P-C, Hidaka H, et al. Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. Lancet Gastroenterol Hepatol. 3(1):37–46. https://doi.org/10.1016/S2468-1253(17)30290-X.

  51. Shiah HS, Chen CY, Dai CY, Hsiao CF, Lin YJ, Su WC, et al. Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. Aliment Pharmacol Ther. 2013;37(1):62–73. https://doi.org/10.1111/apt.12132.

    Article  CAS  PubMed  Google Scholar 

  52. Koeberle D, Dufour JF, Demeter G, Li Q, Ribi K, Samaras P, et al. Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). Ann Oncol. 2016;27(5):856–61. https://doi.org/10.1093/annonc/mdw054.

    Article  CAS  PubMed  Google Scholar 

  53. Singal AG, Murphy CC. Hepatocellular carcinoma: a roadmap to reduce incidence and future burden. J Natl Cancer Inst. 2018; https://doi.org/10.1093/jnci/djy184.

  54. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017; https://doi.org/10.1016/s0140-6736(17)31046-2.

  55. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018; https://doi.org/10.1016/S1470-2045(18)30351-6.

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA

    Amit Mahipal

  2. Department of Internal Medicine, University of South Carolina School of Medicine, Columbia, SC, USA

    Anuhya Kommalapati

  3. Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA

    Rutika Mehta & Richard D. Kim

Authors
  1. Amit Mahipal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anuhya Kommalapati
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rutika Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Richard D. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard D. Kim .

Editor information

Editors and Affiliations

  1. Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA

    Yujin Hoshida

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Mahipal, A., Kommalapati, A., Mehta, R., Kim, R.D. (2019). Molecular-Targeted Therapies in Hepatocellular Carcinoma. In: Hoshida, Y. (eds) Hepatocellular Carcinoma. Molecular and Translational Medicine. Humana, Cham. https://doi.org/10.1007/978-3-030-21540-8_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-21540-8_11

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-21539-2

  • Online ISBN: 978-3-030-21540-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation